Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05609630 · ClinicalTrials.gov registry record · Phase 3
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
A Phase 3 study of Juvenile Idiopathic Arthritis, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
- 20
- Study locations
NCT05609630 is a Phase 3 study of Juvenile Idiopathic Arthritis that is actively recruiting participants, run by AbbVie. The registered enrollment target is 90 participants, below the 291-participant average among 8 other Juvenile Idiopathic Arthritis trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT05609630, a Phase 3 study of Juvenile Idiopathic Arthritis, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
- 20
- Study locations
Study Summary
Juvenile Idiopathic Arthritis (JIA) is the most common type of arthritis that affects children. The term "idiopathic" means "of unknown origin". It is a chronic (long-lasting) disease that causes swelling, warmth, and pain of one or more small joints. Systemic JIA ia a rare and serious form of JIA. Systemic" means it may affect not only the joints but other parts of the body, including the liver, lungs and heart. sJIA is more severe and can be more challenging to diagnose and treat than other types of juvenile idiopathic arthritis. It is a lifelong disease for many patients and can continue into adulthood. This study will assess how safe and effective upadacitinib is in treating pediatric and adolescent participants aged 1 to \< 18 with systemic juvenile idiopathic arthritis (sJIA) and will include a tocilizumab treatment arm for reference. Adverse events and change in the disease activity will be assessed. Upadacitinib is an investigational drug being developed for the treatment of sJIA. Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive upadacitinib or tocilizumab reference. In cohort 2, participants will receive upadacitinib. Approximately 90 participants with sJIA will be enrolled in approximately 45 sites worldwide. Participants will receive upadacitinib oral tablets once daily or oral solution twice daily or tocilizumab subcutaneous injection or intravenous infusion as per local label for 52 weeks and followed for approximately 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits/calls during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.
Conditions Studied
Interventions
- DRUG Upadacitinib
- DRUG Tocilizumab
Study Locations (20)
Other
- Hospital de Niños de la Santisima Trinidad /ID# 252736 - Córdoba
- Hospital Sao Paulo /ID# 251765 - São Paulo
- Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao /ID# 251764 - São Paulo
Victoria
- Monash Health - Monash Medical Centre /ID# 251691 - Clayton
- Royal Children's Hospital /ID# 251663 - Parkville
Arizona
- Phoenix Children's Hospital /ID# 253403 - Phoenix
District of Columbia
- Childrens National Medical Center /ID# 253344 - Washington D.C.
New York
- New York Medical College /ID# 253437 - Valhalla
North Carolina
- Levine Children's Hospital /ID# 253491 - Charlotte
Ohio
- Cincinnati Childrens Hospital Medical Center /ID# 251827 - Cincinnati
Oregon
- Randall Children's Hospital /ID# 251829 - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-10-02 |
| Est. Completion | 2029-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05609630
The ClinicalTrials.gov registry entry for NCT05609630 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 291-participant average among 8 other Juvenile Idiopathic Arthritis trials with a reported enrollment target (69% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Juvenile Idiopathic Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Upadacitinib is the first listed.
NCT05609630 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Other, Victoria, Arizona.
Frequently Asked Questions
What is clinical trial NCT05609630 about?
NCT05609630 is a clinical study titled "Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.". Juvenile Idiopathic Arthritis (JIA) is the most common type of arthritis that affects children. The term "idiopathic" means "of unknown origin". It is a chronic (long-lasting) disease that causes swelling, warmth, and pain of one or more small joints. Systemic JIA ia a rare and serious form of JIA. ...
What is the current status of trial NCT05609630?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2023-10-02. Estimated completion is 2029-06.
What conditions does trial NCT05609630 study?
This clinical trial studies the following conditions: Juvenile Idiopathic Arthritis.
What interventions are being tested in trial NCT05609630?
The interventions under investigation include: Upadacitinib (DRUG), Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT05609630?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05609630 being conducted?
This trial has 20 study locations across Arizona, District of Columbia, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Juvenile Idiopathic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions
RECRUITING
-
Pain in Juvenile Arthritis
RECRUITING · NA
-
An Observational Registry of Abatacept in Patients With Juvenile Idiopathic Arthritis
ACTIVE NOT RECRUITING
-
Juvenile Idiopathic Arthritis (JIA) Registry
COMPLETED
-
Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
COMPLETED · Phase 2
-
Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.